tcsc2115 Ulixertinib

Ulixertinib (VRT752271) is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with IC₅₀ of <0.3 nM against ERK2.

IC50 & Target: IC50: <0.3 nM (ERK2)^[2]

In Vitro: Ulixertinib (VRT752271) is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with IC₅₀ of <0.3 nM against ERK2^[2].

In Vivo: In the pharmacokinetic study, the sensitivity and specificity of the assay are found to be sufficient for accurately characterizing the plasma pharmacokinetics of Ulixertinib in Balb/C mice^[1].